Abstract��
In order to make a more rational clinical use of methotrexate and reduce adverse reactions, we summarize the factors that might cause excretion delay of high-dose methotrexate. METHODS After consulting relevant domestic and overseas documents published recently, we summed up some factors that might cause excretion delay of high-dose methotrexate. RESULTS AND CONCLUSION Physiological states of patients, drug interactions, drug-metabolizing enzymes, and many other factors all may lead to excretion delay of methotrexate. Therefore, we should pay attention to these factors to reduce the incidence of excretion delay and ensure safe medication in clinical application of methotrexate.
PANG Lu,
LIU Li-Min,
ZHAO Li-Mei-*
.Research Progress in Influence Factors of Excretion Delay of High-dose Methotrexate[J] Chinese Pharmaceutical Journal, 2013,V48(22): 1892-1896
��
[1]
XU W Q,TANG Y M,FANG C Q,et al. Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia. Chin J Hematol(�л�ѪҺѧ��־),2005,26(1):15-18.[2] JAHNKE K,KORFEL A,MARTUS P,et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol,2005,16(3):445-449.[3] CREWS K R,LIU T,RODRIGUEZ-GALINDO C,et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer,2004,100(8):1724-1733.[4] JOANNON P,OVIEDO I,CAMPBELL M,et al. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: Lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer, 2004,43(1):17-22.[5] SKARBY T,JONSSON P,HJORTH L,et al. High-dose methotrexate: On the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL) . Cancer Chemother Pharmacol,2003,51(4):311-320.[6] YE M,FU Q,LI P,et al. High dose methotrexate population pharmacokinetics and bayesian estimation in patients with lymphoid malignancy . Chin Pharm J(�й�ҩѧ��־),2009,44(5):367-372.[7] LIN X W,SHAO H,NIE X Y,et al. Influence of creatinine clearance on serum methotrexate concentration in high-dose methotrexate therapy . Chin J Clin Pharmacol and Ther(�й��ٴ�ҩ��ѧ������ѧ��־),2009,14(3):319-322.[8] LI J,GWILT P. The effect of malignant effusions on methotrexate disposition . Cancer Chemother Pharmacol,2002,50(5):373-382.[9] KAWAKAMI M,OMORI H,YAMAGAMI T,et al. Prolonged accumulation of high-dose methotrexate in a case with large liver cysts. Cancer Chemother Pharmacol,2009,64(3):619-622. JOERGER M,HUITEMA A D,BONGARD H J,et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol,2006,62(1):71-80. REID T,YUEN A,CATOLICO M,et al. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol,1993,33(1):82-84. BREEDVELD P, ZELCER N, PLUIM D,et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: Potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res, 2004,64(16):5804-5811. BEORLEGUI B, ALDAZ A, ORTEGA A,et al. Potential interaction between methotrexate and omeprazole. Ann Pharmacother,2000,34(9):1024-1027. BAUTERS T G, VERLOOY J, ROBAYS H,et al. Interaction between methotrexate and omeprazole in an adolescent with leukemia: A case report. Pharm World Sci,2008 ,30(4):316-318. SUZUKI K, DOKI K, HOMMA M, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol,2009,67(1):44-49. SANTUCCI R, LEVEQUE D, LESCOUTE A,et al. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res,2010,30(9):3807-3810. SANTUCCI R, LEVEQUE D, KEMMEL V, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res,2010,30(3):963-963. RANCHON F, VANTARD N, GOURAUD A, et al. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: A case report - should the practice be changed. Chemother,2011,57(3):225-229. THYSS A, MILANO G, KUBAR J,et al. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet,1986,1(8475):256-258. UWAI Y, TANIGUCHI R, MOTOHASHI H,et al. Methotrexate-loxoprofen interaction: Involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet,2004,19(5):369-374. EL-SHEIKH A A, VAN DEN HEUVEL J J, KOENDERINK J B, et al. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther,2007,320(1):229-235. BLUM R, SEYMOUR J F, TONER G. Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Ann Oncol,2002,13(2):327-330. SHAMASH J, JOEL S, LUNDHOLM L, et al. High-dose methotrexate clearance following prior vancomycin administration: No significant interaction in the absence of overt renal impairment. Ann Oncol, 2003,14(1):169-170. VAN HEST R M, SCHNOG J B, VAN��T VEER M B, et al. Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinib. Am J Hematol,2008,83(9):757-758. EL-KHODARY N M, EL-HAGGAR S M, EID M A, et al. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol,2012,29(3):2053-2062. IMANISHI H, OKAMURA N, YAGI M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet,2007,52(2):166-171. FAGANEL K B, GRABNAR I, BOHANEC GRABAR P, et al. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol,2011 ,67(10):993-1006. XU K K,LIAO Q C,ZHANG Y, et al. Influence of MTHFR C677T and RFC1 G80A gene polymorphisms on adverse reactions of high dose methotrexate chemotherapy in children with acute lymphoblastic leukemia . J Appl Clin Pediatr(ʵ�ö����ٴ���־),2009,24(21):1674-1676. KANTAR M,KOSOVA B, CETINGUL N, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma,2009,50(6):912-917. LAVERDIERE C, CHIASSON S, COSTEA I, et al. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood, 2002,100(10):3832-3834. FAGANEL KOTNIK B, DOLZAN V, GRABNAR I, et al. Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma,2010,51(4):724-726. VLAMING M L,VAN ESCH A, PALA Z,et al. Abcc2(Mrp2), Abcc3 (Mrp3), and Abcg2(Bcrp1)are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther,2009,8(12):3350-3359. HULO J S, VILLARD E, MAGUY A, et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics,2005,15(5):277-285 . SANTUCCI R, LEVEQUE D, HERBRECHT R. Cola beverage and delayed elimination of methotrexate. Br J Clin Pharmacol,2010,70(5):762-764. RELLING M V, FAIRCLOUGH D, AYERS D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol,1994,12(8):1667-1672.
2013, Vol. 48 
